



## **Emerald Health Therapeutics' Cannabis Sublingual Tablet Provides Consumers with Predictable Action and Advances Defined Dose™ Offering**

**First-to-market rapidly-dissolving tablet offers controlled onset and offset; reflects Emerald's focus on science-based innovation and expands products available under SYNC™ Wellness brand**

VANCOUVER, BC, April 13, 2021 /CNW/ – Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has launched its new product line, SYNC™ Tabs, an innovative, naturally-flavoured ingestible offering consumers a controlled 10 mg THC dose with predictable onset and offset. This product line expands its offering under its SYNC™ Wellness brand and is the second of Emerald's Defined Dose™ products. The first provincial purchase orders have been received and, beginning April 13<sup>th</sup>, the tablets will be available to consumers at licensed cannabis retailers and online in BC, Manitoba, and Newfoundland, with Alberta to follow.



Emerald's Cannabis 2.0 and 3.0 strategy focuses on leveraging science-based innovation to serve targeted consumer preferences. This differentiated new product line builds on Emerald's commitment to offering consumers defined dosing and predictable actions that let them control their cannabis consumption experience. SYNC™ Tabs are designed in a familiar tablet form that enables convenient yet discreet cannabis use.

With 10 mg of THC, SYNC™ Tabs offer consumers the measured stringency of Emerald's Defined Dose™ standard, dissolve under the tongue in about three minutes, and provide desired

effects within 20 to 30 minutes. Offset is equally controlled, occurring within approximately 90 minutes of taking the tablet. This new product line follows the introduction of Emerald's Nano Fast-Acting Spray product. Sublingual tablets add to the SYNC™ brand's line-up of non-smoking forms of cannabis products, which also include CBD and THC cannabis oils.

Designed to serve customers' use of cannabis for daily wellness routines, SYNC™ Tabs are sugar-free, gluten-free, vegan and come in two natural flavours, cherry and mint. Produced with 100-percent coconut-derived MCT oil, the products offer a sustainably-produced cannabis wellness option. Each pack contains 10 x 10 mg doses, offering 100 mg of THC in total.

"Our product development efforts are centered on providing consumers with distinctive cannabis products offering controlled, predictable actions – with greater precision of dosing and the onset and offset of effects," said Riaz Bandali, President and CEO. "We have a talented product development team that is passionate about science and innovation. They are moving additional new product lines toward launches planned for the next few months and quarters, which we expect to start positively impacting our growth."

### **About SYNC™**

SYNC™ Wellness is dedicated to helping create balance in everyday life through innovative "smoke-free" cannabis products that are discreet and made with natural ingredients. Enjoy SYNC™ products any time of day with the confidence of precise and defined dosing. Focused on a holistic approach to cannabis consumption to fit your lifestyle, you will be able to incorporate SYNC™ into your everyday wellness routine. For more information about SYNC™ Tabs, visit [www.emeraldhealth.ca/products/sync-wellness](http://www.emeraldhealth.ca/products/sync-wellness).  
[@syncwellness.ca](https://twitter.com/syncwellness.ca)



### **About Emerald Health Therapeutics**

Emerald is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products with an emphasis on innovation and product excellence.

Please visit [www.emeraldhealth.ca](http://www.emeraldhealth.ca) for more information or contact:

Jenn Hepburn, Chief Financial Officer  
(800) 757 3536 Ext. #5

Emerald Investor Relations  
(800) 757 3536 Ext. #5  
[invest@emeraldhealth.ca](mailto:invest@emeraldhealth.ca)

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements.*

*We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, changes of law and regulations; changes of government; failure to obtain regulatory approvals or permits; failure to obtain necessary financing; results of product development, production and sale activities; changes in prices and costs of inputs; demand for products; changes in business strategy; as well as the risk factors described in Emerald's annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Emerald undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.*